Drug Profile
Research programme: matrix metalloproteinase-12 inhibitors - Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Small molecules
- Mechanism of Action Matrix metalloproteinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (PO)
- 31 Mar 2011 This programme is still in active development